Cardiac mortality, adequate power, and objective inclusion of the entire evidence are key to accurately define the long-term effect of revascularisation vs. medical therapy alone in stable coronary syndromes

This commentary refers to 'Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis', by E.P. Navarese et al., https:// doi.org/10.1093/eurheartj/ehab246; 'When a meta-analysis equals a single large-scale trial with meaningful follow-up', by E.P. Navarese et al., https://doi:10.1093/eurheartj/ ehab460; and the discussion pieces 'Cardiac death should be the primary endpoint for revascularisation trials and meta analyses', by H.D. White, https://doi.org/10.1093/ eurheartj/ehab676; `In the pool: dilution or drowning?'